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Using an ultra-sensitive technique, an immunomagnetic reduction assay, the plasma tau
level can be measured to a limit of quantification of pg/ml. In total 126 cognitively normal
middle-aged and older adults (45–95 years old) were recruited. The plasma tau levels
were significantly higher in the older group (aged 65–95 years) 18.14 ± 7.33 pg/ml than
those in the middle-aged group (aged 45–64 years) 14.35 ± 6.49 pg/ml when controlled
gender and ApoEε4 carrier status (F = 3.102, P = 0.029). The ApoEε4 carriers had higher
plasma tau levels than the non-carriers when controlled age and gender (F = 6.149,
P = 0.001). Men had higher plasma tau levels than their women counterparts when
controlled ApoEε4 carrier status and gender (F = 6.149, P = 0.001). The plasma tau
levels were found to be positively associated with their ages (r = 0.359, P < 0.001).
Regression analysis showed that age explained approximately 13% of the variance in the
plasma tau levels, and explained more than 10% of the variance in the volumes of the
hippocampus and white matter hypodensity (R2 change 0.123∼0.167, all P < 0.001),
and explained less than 10% of the variance in the volume of the amygdala, and central
part of the corpus callosum (R2 change 0.085∼0.097, all P = 0.001). However, the
plasma tau levels do not further explain any residual variance in the volume of brain
structures. In conclusion, the effect of age on the plasma tau levels should always be
considered in clinical applications of this surrogate biomarker to middle-aged and elderly
subjects.
Keywords: age, immunomagentic reduction assay, plasma tau, biomarker, normal cognition
INTRODUCTION
Diagnosis of preclinical Alzheimer’s disease (AD) or other suspected non-Alzheimer pathologies
depends on the evidence of genetic carrier status and pathophysiological changes in the brain,
such as shown by fluid and imaging biomarkers. Neuronal injury or neurodegeneration-
associated biomarkers provide clinicians to monitor progression of cognitive impairment, to
predict prognosis, and to evaluate therapeutic outcomes of disease-modifying interventions
in clinical trials (Buerger et al., 2009). Elevation of the tau level in cerebrospinal fluid (CSF)
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FIGURE 1 | Shows that age is positively associated with the plasma
tau level and explains approximately 13% of the variance (R2 change
0.129, F = 18.329, P < 0.001) in the plasma tau levels; the upper and
lower lines indicate the 95% confidence intervals.
may suggest active axonal and neuronal destruction (Tapiola
et al., 2009). Patients with AD were reported to have three-fold
higher CSF tau levels (Hampel et al., 2008); some considered
it is a potential biomarker of AD (Lewczuk et al., 2017); and
even might predict a rapid progression from mild cognitive
impairment (MCI) to AD-associated dementia (van Rossum
et al., 2012). However, in addition to patients with AD, increased
total tau levels in the CSF of patients with certain other
neurological diseases, such as acute stroke, Creutzfeldt-Jakob
disease and natalizumab-treated multiple sclerosis (Otto et al.,
1997; Hesse et al., 2000; Kapaki et al., 2001; Llorens et al., 2016;
Mellergård et al., 2017). Acute traumatic brain injury may also
cause increased release of tau protein into the CSF (Zemlan et al.,
1999).
The tau level in the CSF has been associated with hippocampal
atrophy in some studies (Hampel et al., 2005; Desikan et al.,
2011; de Souza et al., 2012). The tau level in the CSF also
correlates to severity of brain atrophy in the abovementioned
natalizumab-treated multiple sclerosis patients at the 3-year
follow-up (Mellergård et al., 2017).
The plasma tau levels of patients with neurological diseases
have not been well studied until recently. Recent studies have
found that plasma tau levels were increased during the acute
phase (Randall et al., 2013) and late phase (Mortberg et al.,
2011) of hypoxic brain injury following cardiac arrest. A study
on Olympic boxers, who suffered from repetitive non-knocked-
out head concussions from boxing bouts, plasma tau levels were
elevated within 1–6 days of a bout and returned to normal after
resting at least for a period of 14 days (Neselius et al., 2013).
Zetterberg et al. (2013) applied a singlemolecule array (SimoaTM)
assay to quantitatively evaluate the total tau protein level in
plasma and found that the plasma tau protein concentration of
AD patients is higher than those of MCI patients and normal
controls. Chiu et al. (2013) assayed the plasma tau protein level
using an immunomagnetic reduction assay and showed that the
levels of plasma tau protein are higher in patients with MCI
due to AD and in patients with AD dementia than in normal
controls.
However, no study has explored the effect of aging on the
plasma tau protein level in normal population due to the even
lower concentration of tau protein in the plasma of normal
subjects. The aims of the present study were to elucidate the
effect of age on the plasma tau levels of cognitively normal
middle-aged and older adults and to explore possible correlations
between brain structures and the plasma tau protein levels in
these cognitively normal subjects.
MATERIALS AND METHODS
Subjects
The volunteers who participated in this study were asked to
complete a medical checklist regarding major systemic diseases,
operations and hospitalizations. Volunteers who reported having
uncontrolled medical conditions, including heart failure, a
recent myocardial infarction (within the past 6 months),
malignancy (within the past 2 years) or poorly controlled diabetes
(HbA1C> 8.5), were excluded. Volunteers also received physical
and neurological examinations and were scored on a short-form
geriatric depression scale (GDS-S). Those who had a GDS-S
score of greater than 9 were excluded. All of the participants
provided written informed consent prior to participating in this
investigation. The study was approved by the ethics committee
and the institutional review board of the National Taiwan
University Hospital (protocol 201301036-RIND). The study was
carried out in accordance with the Helsinki Declaration of 1975.
Cognitive and Functional Assessments
The assessments performed in this study included determining
the clinical dementia rating (CDR) scores and the scores on the
short-form geriatric depression scale (GDS-S); additionally, the
Taiwanese mental status examination (TMSE), two subtests of
the Wechsler memory scale (WMS)-III logical memory subtest
and family picture subtest were performed (Hua et al., 2005).
For the cognitive assessments, the participants had to be within
normal limits (scores higher than 1.5 standard deviation) of
age- and education-matched normal subjects. None of the
participants met the diagnostic guidelines for all causes of
dementia or MCI proposed by the NIA-AA workgroups in 2011
(Albert et al., 2011; McKhann et al., 2011).
Structural MRI
High-resolution brain structural brain MRI scans were acquired
using a 1.5 T MRI scanner (EXCITE, General Electric,
Milwaukee, Wisconsin, USA). A whole-brain T1-weighted
3D spoiled gradient recovery (SPGR) sequence was used
(TE = 9.3 ms, TR = 3.9 ms, TI = 600 ms, flip angle = 12◦,
matrix size = 192 × 192 and FOV = 25 cm), and 170 images
of contiguous sagittal slices that were 1.3 mm in thickness
were acquired. The analyzed datasets include the T1-weighted
structural MRI scans obtained from all of the available subjects
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(n = 123). The MRI images were corrected for intensity
inhomogeneity and were reoriented, after which they were
registered against MNI 152 space using FSL (FMRIB Software
Library) FIRST tools (Smith et al., 2004). Image analysis
to determine the cortical thickness, gray matter volume and
white matter hypodensity were performed using the FreeSurfer
software package (version 5; Athinoula A. Martinos Center for
Biomedical Imaging, Boston, MA, USA) on an AAL template.
Plasma Tau Protein Assays
Participants were asked to provide a 10-ml non-fasting venous
blood sample (K3 EDTA, lavender-top tube). The blood samples
were centrifuged (2500× g for 15 min) within 1 h of collection,
and the plasma was aliquoted into cryotubes and stored at−80◦C
for less than 3 months until it was thawed for measurement
of the tau levels via an immunomagnetic reduction assay.
The reagent (MF-TAU-0060, MagQu) used to determine the
plasma tau protein levels consisted of dextran-coated Fe3O4
nanoparticles functionalized with antibodies directed against
tau protein. In brief, the anti-tau antibody (Sigma, T9450) was
derived from mouse monoclonal clone tau46 which recognizes
bovine, rat, human and mouse tau. This monoclonal antibody
also recognizes a phosphorylation-independent epitope in amino
acids 404–441 (human) and all six isoforms of tau thusmeasuring
total tau. The mean diameter of the nanoparticles was 53 nm.
The antibody-functionalized nanoparticles are well dispersed in a
phosphate-buffered saline solution of pH 7.2. A SQUID-based ac
magnetosusceptometer (XacPro-S, MagQu) was used to analyze
the samples. A 60-µl aliquot of plasma was mixed with 60 µl of
reagent at room temperature for determination of the tau protein
concentration. The underlying mechanism and the technological
details of the immunomagnetic reduction assay are described in
our previous reports (Chiu et al., 2012; Yang et al., 2013).
Statistical Analyses
Independent t-test was used to examine between-group
difference of parametric variables of demographic and clinical
data. Pearson chi square was used to examine distribution
of non-parametric data such as gender and ApoEε4 carrier
status. One-way ANCOVA (analysis of covariance) was used
to compare plasma tau levels between different age groups
(middle-aged vs. older subjects), genders and ApoEε4 carrier
status. Pearson correlation test was applied to identify brain
structures as significant dependent variables of stepwise linear
regression analysis. Stepwise linear regression analysis was used
to evaluate the percentage of the variance explained by the
independent variables.
RESULTS
We recruited 126 cognitively normal adults aged 45–95 years
(mean: 66.7 ± 9.6) of whom 61.1% were women. The subjects
included 56 middle-aged (45–64) and 70 older (65–95) adults
(Table 1). There was a significant difference in the plasma tau
levels between the middle-aged and older adults (F = 3.102,
P = 0.029) when controlled for the effects of gender and
ApoEε4 carrier status. There was also a significant between-
group difference in the plasma tau levels of ApoEε4 carriers
(17.29 ± 6.89 pg/ml) and non-carriers (16.27 ± 7.28 pg/ml,
F = 6.149, P = 0.001) when controlled for the effects of age
and gender. Gender also significantly affected the plasma tau
levels (men 17.11 ± 7.16 pg/ml, women 16.05 ± 7.23 pg/ml,
F = 6.149, P = 0.001) when controlled for the effects of age and
ApoEε4 carrier status.
Correlation analyses showed that age was negatively
correlated with the TMSE scores (r = −0.543, P < 0.001),
whereas age was positively correlated with the plasma tau
TABLE 1 | Demographic and clinical information of the participants.
Subjects (numbers) All (126) Middle-aged (56) Older (70)
Years of age (range) 66.7 ± 9.6 (45–95) 58.1 ± 4.9 (45–64) 73.6 ± 6.3 (65–95)
Gender women % 61.6 70.9 54.3∗
Years of education 13.2 ± 3.7 13.5 ± 3.5 13.0 ± 3.9∗
TMSE score 28.5 ± 1.6 29.0 ± 1.3 28.2 ± 1.8
ApoEε4 (%) 18.3 14.3 21.4∗
Plasma tau (pg/ml) 16.46 ± 7.2 14.35 ± 6.49 18.14 ± 7.33†
TMSE, Taiwan mental status examination; ApoEε4, prevalence of apolipoprotein Eε4; ∗No significant between-group difference in items listed; †Significant group difference
when controlled for gender and ApoEε4 carrier status by ANCOVA, F = 3.102, P = 0.029.
TABLE 2 | Stepwise multiple linear regression analyses with measurements of brain structures as dependent variables and age, gender, education and
tau as independent variables.
Brain structure Model R2 change F Significance
RHippocampus Vol Model I Age 0.167 23.607 <0.001
RHippocampus Vol Model II ApoEε4 0.03 4.390 0.038
LHippocampus Vol Model I Age 0.131 17.836 <0.001
RAmygdala Vol Model I Age 0.086 11.131 0.001
LAmygdala Vol Model I Age 0.097 12.622 0.001
CC central Vol Model I Age 0.085 10.949 0.001
WM hypodensity Model I Age 0.123 16.561 <0.001
TMSE, Taiwanese mental status examination; L/R, left/right; CC, corpus callosum; Vol, volume.
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levels (Pearson r = 0.359, P < 0.001; Figure 1). We performed
the Bonferroni adjustment to control the family-wise error
rate derived from multiple comparisons of brain structures
(P defined as 0.001). Image analyses showed that age was
significantly negatively correlated with the volumes of the
bilateral hippocampus (left r = −0.362 and right r = −0.408,
both P < 0.001), bilateral amygdala (left r = −0.311 and right
r = −0.294, both P = 0.001), and the volumes of the central
part of the corpus callosum (r = −0.291, P = 0.001), whereas
age was positively correlated with the volume of white matter
hypodensity (r = 0.351, P < 0.001). A partial correlation analysis
was performed to explore the relationship between plasma tau
levels and measurements of brain structures by controlling age
effect. The plasma tau levels were not significantly correlated
with both the volume of the subcortial brain structures and
thickness of various cortical regions when controlled age effect.
Further analyses using stepwise linear regression showed that
age explained approximately 13% of the variance in the plasma
tau levels (R square (R2) change 0.129, F = 18.329, P < 0.001)
excluded the years of education, gender and ApoE4 carrier
status (Figure 1). In addition, age explained more than 10% of
the variance in the hippocampal volumes (R2 change 0.1321,
F = 17.836 for the left and R2 change 0.167, F = 23.607 for the
right, both P < 0.001) and white matter hypodensity (R2 change
0.123, F = 16.561, P < 0.001) excluded the years of education,
gender, plasma tau levels and ApoE4 carrier status (Table 2).
ApoE4 carrier status explained only additional 3% of the variance
of the right hippocampal volume (R2 change 0.03, F = 4.390,
P = 0.038; Table 2). Age explained less than 10% of the variance
in the amygdala volume (R2 change 0.097, F = 12.622 for the left
and R2 change 0.086, F = 11.131 for the right, both P = 0.001)
excluded the years of education, gender, plasma tau levels and
ApoE4 carrier status (Table 2).
DISCUSSION
Recently Mattsson et al. (2016) reported that higher plasma tau
associated with AD dementia, higher CSF tau and lower CSF
Aβ. Thus, plasma tau levels may at least in part reflect the
CSF tau levels. A previous study found a correlation between
age and the CSF tau level (Sjögren et al., 2001). The aging-
related elevation of the plasma tau protein levels found in the
cognitively normal middle-aged and older adults in this study
might be a consequence of the normal aging process of the
brain. The elevated plasma tau levels may imply the increasing
production of tau protein in the brain with increasing age.
This hypothesis is compatible with the age-related increment in
tau related pathology, such as tangle formation and neuronal
loss, even in non-demented aging individuals (Ball, 1977; Terry
et al., 1987; Price and Morris, 1999). Plaques were absent
in some of the brains of the non-demented elderly, and
the earliest plaque formation in other brains was found to
have occurred in the neocortex, in patches of diffuse plaques
(Price and Morris, 1999). This type of aging-related structural
change was also reflected in the findings of the present study,
in which quantitative aspects of some brain areas, such as the
volumes of the hippocampus, amygdala and the central part of
the corpus callosum were negatively associated with the age,
whereas the volume of white matter hypodensity was positively
associated with the age. However, the regional specificity and
age-related linearity of age-related brain volume changes remain
controversial (Terribilli et al., 2011). Although tau protein levels
might reflect a certain degree of neuronal loss and consequent
regional brain atrophy, this phenomenon can be well explained
in great part by the aging process because stepwise regression
analysis showed that the brain structural values was mostly
explained by the aging effect and no additional effect was
explained by increasing or decreasing plasma tau protein levels.
In an interesting contrast, plasma tau levels were found to be
negatively correlated with the hippocampal and brain volumes
of patients with MCI due to AD or mild AD (Chiu et al., 2014)
but not with those of cognitively normal controls in this study.
This result might imply that the plasma tau level is useful as
a surrogate biomarker representing disease severity rather than
only the effect of aging and that it can be used to monitor disease
progression or beneficial responses to current disease-modifying
therapies.
The ApoEε4 carriers had higher plasma tau levels than
did their non-carrier counterparts. ApoEε4 carrier status
significantly increases the risk of developing AD via both
amyloid-related and non-amyloid-related mechanisms
(Kanekiyo et al., 2014). ApoEε4 promotes amyloid deposition in
the brain, which may further result in the appearance of tau in
the brain through the ‘‘Aβ-induced tau pathology’’ mechanism
(Stancu et al., 2014). Gender also had an effect on the plasma tau
levels that men had higher plasma tau levles than their women
counterparts. A recent in vitro study showed that the male
sex hormone testosterone was more efficient in lessening Aβ-
induced mitochondria deficits, while the women sex hormone
progesterone and estrogen were the most effective neurosteriods
in AD related tauopathy (Grimm et al., 2016).
To the best of our knowledge, this is the first report
demonstrating the tau levels in the blood of cognitively,
neurologically and psychiatrically normal middle-aged and older
individuals. Knowledge of the tau level in the blood is more
useful than is knowledge of that in the CSF due to the much
easier access to blood and the greater clinical convenience and
safety of blood collection. One of the most important strength
of the present study is that our ultra-sensitive IMR method
(limit of detection lower than pg/ml) is able to demonstrate
the age effect on tau levels in the blood. The plasma levels
of tau measured in this study are higher (about twofold) than
those in the previous studies using either conventional enzyme-
linked immunosorbent assay (ELISA) or other ultra-sensitive
technology such as the SimoaTM digital ELISA (Zetterberg et al.,
2013). The reasons may include that IMR is more resistant to
the interference from other components in the blood such as
albumin or bilirubin; the preparation of our sample is quite
straightforward avoiding loss of target protein during multi-step
processing; also our tau antibody recognizes all isoforms of tau
therefore achieve higher measures (Chiu et al., 2013; Yang et al.,
2013).
However, this study is not without limitations. First, because
our subjects included middle-aged to elderly adults but did
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not include young adults, such as those with ages in the
range of 20–44 years old, care must be taken in generalizing
the results of age effect of the present report. Second, this
was a cross-sectional study, and a longitudinal study of the
same individuals over a long period, such as 5–10 years,
might validate our findings of the age-related increase in
the plasma tau level. Also, lack of longitudinal follow-up,
there is a potential risk of including subjects with preclinical
neurodegenerative disease such as AD or other tauopathy into
the study population. The current study, therefore, warrants
a long-term follow-up study. Third, we did not have data
of the CSF tau levels to cross-validate our findings because
Asian people, particularly older people, are rather reluctant
to submit to a lumbar puncture. Also information of CSF
and/or plasma Aβ42 or p-tau is not available in this study.
However, this phenomenon indicates the importance of our
report because the ultra-sensitive assay we employed allows
quantifying the ultra-low tau levels in the blood and allows a
safer andmore comfortable assessment of the level of a neuronal-
injury biomarker.
CONCLUSION
The study demonstrated that age affects the level of plasma
tau protein the same as the level of CSF tau protein found
in a previous study (Sjögren et al., 2001). Thus, we must
consider the age effect when using either the plasma or CSF tau
level as a surrogate biomarker for axonal/neuronal damage or
degeneration.
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